Last reviewed · How we verify
Lacidofil
At a glance
| Generic name | Lacidofil |
|---|---|
| Sponsor | Dr. Stephen Freedman |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia (PHASE4)
- Efficacy and Safety of Lacidofil® STRONG as an Adjuvant for Helicobacter Pylori Treatment in Non-ulcer Dyspepsia (PHASE2, PHASE3)
- The Effect of Probiotic Intake on Intestinal Permeability in Healthy Adults (NA)
- Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly (PHASE4)
- Emergency Department Probiotic Treatment of Pediatric Gastroenteritis (PHASE3)
- Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis (PHASE4)
- Effect of a Lacidofil® STRONG in Healthy Adults Taking Antibiotic Treatment (PHASE1, PHASE2)
- Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lacidofil CI brief — competitive landscape report
- Lacidofil updates RSS · CI watch RSS
- Dr. Stephen Freedman portfolio CI